A novel drug interaction between the quinolone antibiotic ciprofloxacin and a chiral metabolite of pentoxifylline

Biochemical Pharmacology

Volumn 74, Issue 4, 2007, Pages 639-646

  Raoul, Jennifer M ^a   Peterson, Marc R ^a   Peterson, Theresa C ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Ciprofloxacin; Drug interaction; Fibrosis; Metabolism; Metabolite 1; Pentoxifylline

Indexed keywords

CIPROFLOXACIN; DRUG METABOLITE; METHYLXANTHINE DERIVATIVE; PENTOXIFYLLINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG METABOLISM; DRUG POTENTIATION; DRUG STRUCTURE; ENANTIOMER; FIBROSIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTI-INFECTIVE AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CIPROFLOXACIN; DRUG INTERACTIONS; HALF-LIFE; INJECTIONS, INTRAPERITONEAL; KINETICS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MICE; MOLECULAR STRUCTURE; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITORS; STEREOISOMERISM; TIME FACTORS;

EID: 34447283989     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2007.05.013     Document Type: Article

References (44)

1. Ward A., and Clissold S.P. PTX, a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy. Drugs 34 (1987) 50-97
2. Samlaska C.P., and Winfield E.A. Pentoxifylline. J Am Acad Deramtol 30 (1994) 603-621
3. Tjon J.A., and Riemann L.E. Treatment of intermittent claudication with pentoxifylline and cilostazol. Am J Health Sys Pharm 58 (2001) 485-493
4. Rieneck K., Diamant M., Haahr P.M., Schonharting M., and Bendtzen K. In vitro immunomodulatory effects of pentoxifylline. Immunol Lett 37 2-3 (1993) 131-138
5. Tilg H., Eibl B., Pichl M., Gachtet A., Herold M., Brankova J., et al. Immune response modulation by pentoxifylline in vitro. Transplantation 56 1 (1993) 196-201
6. H2 balance is modulated by pentoxifylline. J Cardiovasc Pharmacol 25 Suppl. 2 (1995) S80-S84
7. Mytar B., Woloszyn M., Ruggerio I., Pryjma J., and Zembala M. Monocyte-mediated regulation of the antigen-driven IFN gamma production by T cells. Immunol Invest 24 6 (1995) 897-906
8. Rieckmann P., Weber F., Gunther A., Martin S., Bitsch A., Brooks A., et al. Pentoxifylline, a phosphodiesterase inhibitor, induces immune deviation in patients with multiple sclerosis. J Neuroimmunol 64 2 (1996) 193-200
9. Windmeier C., and Gressner A.M. Pharmacological aspects of pentoxifylline with emphasis on its inhibitory actions on hepatic fibrogenesis. Gen Pharmacol 29 2 (1997) 181-196
10. Reimund J.M., Dumont S., Muller C.D., Kenney J.D., Kedinger M., Baumann R., et al. In vitro effects of oxpentifylline on inflammatory cytokine release in patients with inflammatory bowel disease. Gut 40 4 (1997) 475-480
11. Wang W., Tam W.F., Hughes, Rath S., and Sen R. c-Rel is a target of pentoxifylline-mediated inhibition of T lymphocyte activation. Immunity 6 2 (1997) 165-174
12. Peterson T.C., Peterson M.R., Wornell P.A., Blanchard M.G., and Gonzalez F.J. Role of CYP1A2 and CYP2E1 in the pentoxifylline ciprofloxacin drug interaction. Biochem Pharmacol 68 (2004) 395-402
13. Isbrucker R.A., and Peterson T.C. Platelet-derived growth factor and pentoxifylline modulation of collagen synthesis in myofibroblasts. Toxicol Appl Pharmacol 149 (1998) 120-126
14. Peterson T.C., and Tanton R. Effect of pentoxifylline in collagenous colitis. Can J Gastroenterol 10 (1996) S76
15. Pinzani M. Novel insights into the biology and physiology of the Ito cell. Pharmacol Ther 66 (1995) 387-412
16. Preaux A.-M., Mallat A., Rosenbaum J., Zafrani E.-S., and Mauvier P. Pentoxifylline inhibits growth and collagen synthesis of cultured human myofibroblasts-like cells. Hepatology 26 (1997) 315-322
17. Chen Y.-M., Wu K.D., Tsai T.J., and Hseih B.S. Pentoxifylline inhibits PDGF-induced proliferation and TGF-β-stimulated collagen synthesis by vascular smooth muscle cells. J Mol Cell Cardiol 31 4 (1999) 773-783
18. Hewitson T.D., Martic M., Kelynack K.J., Pedagogos E., and Becker G.J. Pentoxifylline reduces in vitro renal myofibroblast proliferation and collagen secretion. Am J Nephrol 20 1 (2000) 82-88
19. Lin S.L., Chen Y.M., Chien C.T., Chien W.C., Tsai C.C., and Tsai T.J. Pentoxifylline attenuated the renal disease progression in rats with remnant kidney. J Am Soc Nephrol 13 12 (2002) 2916-2929
20. Valente E.G.A., Vernet D., Ferrini M.G., Qian A., Rajfer J., and Gonzalez-Cadavid N.F. L-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie's fibrotic plaque and related fibroblast cultures. Nitric Oxide 9 4 (2003) 229-244
21. Peterson T.C., and Isbrucker R.A. Fibroproliferation in liver disease: role of monocyte factors. Hepatology 15 (1992) 191-197
22. Peterson T.C. Pentoxifylline prevents fibrosis in an animal model and inhibits platelet-derived growth factor-driven proliferation of fibroblasts. Hepatology 17 3 (1993) 486-493
23. Peterson T.C., and Neumeister M. Effect of pentoxifylline in rat and swine models of hepatic fibrosis: role of fibroproliferation in its mechanism. Immunopharmacol 31 (1996) 183-193
24. Smith R., Waller E., Doluisio J., Bauza M., Puri S., Ho I., et al. Pharmacokinetics of orally administered pentoxifylline in humans. J Pharm Sci 75 (1986) 47-52
25. Aviado D., and Dettelbach H. Pharmacology of PTX: a hemorrheologic agent for the treatment of intermittent claudication. Angiol 35 (1984) 407-417
26. Crouch S.P.M., and Fletcher J. Effect of ingested pentoxifylline on neutrophil superoxide production. Infect Immun 60 11 (1992) 4504-4509.
27. Peterson T.C. Inhibition of fibroproliferation by pentoxifylline. Activity of metabolite-1 and lack of role of adenosine receptors. Biochem Pharmacol 52 4 (1996) 597-602
28. Isbrucker R.A., and Peterson T.C. Effect of PDGF, PTX and M-1 on collagen synthesis in porcine hepatic stellate cells. Hepatology 22 (1995) 4
29. Thompson J.A., Bianco J.A., Benyunes M.C., Neubauer M.A., Slattery J.T., et al. Phase 1b trial of pentoxifylline and ciprofloxacin in patients treated with interleukin-2 and lymphokine-activated killer cell therapy for metastatic renal carcinoma. Cancer Res 54 (1994) 3436-3441
30. Wornell P.A., and Peterson T.C. Investigation of the PTX/CIPRO drug interaction in the mouse. Hepatology 26 (1997) 453A
31. Peterson T.C., Isbrucker R., and Hooper M.L. In vitro effect of platelet-derived growth factor on fibroproliferation and effect of cytokine antagonists. Immunopharmacology 28 (1994) 259-270
32. Ege S. Stereochemistry. In: Hamann K.P., Williams J., Wise K., Merill L., and Roll M. (Eds). Organic Chemistry: structure and reactivity (1994), D.C. Heath and Co., USA 196-240
33. Hodgson P.D., and Peterson T.C. Effect of PTX in a heterologous serum model of fibrosis. Hepatology 22 (1995) 4
34. Blanchard M.G., and Peterson T.C. Increased level of antifibrotic drugs due to selective inhibition of CYP1A2. Hepatology 30 (1999) 558A
35. Nicklasson M., Bjorkman S., Roth B., Jonsson M., and Hoglund P. Stereoselective metabolism of pentoxifylline in vitro and in vivo in humans. Chirality 14 (2002) 643-652
36. Lillibridge J.A., Kalhorn T.F., and Slattery J.T. Metabolism of lysofylline and pentoxifylline in human liver microsomes and cytosol. Drug Metab Dispos 24 11 (1996) 174-179
37. Lee S.H., and Slattery J.T. Cytochrome P450 isozymes involved in lisofylline metabolism to pentoxifylline in human liver mocrosomes. Drug Metab Dispos 25 12 (1997) 1354-1358
38. Fuhr U., Anders E.M., Mahr G., Sorgel F., and Staib A.H. Inhibitory potency of quinolone antibacterial agents against cytochrome P4501A2 activity in vivo and in vitro. Antimicrob Agents Chemother 36 (1992) 942-948
39. Herrlin K., Segerdahl M., Gustafsson L.L., and Kalso E. Methadone, ciprofloxacin and adverse drug reactions. Lancet 356 (2000) 2069-2070
40. Peterson T.C., Slysz G., and Isbrucker R. The inhibitory effect of ursodeoxycholic acid and pentoxifylline on platelet derived growth factor-stimulated proliferation is distinct from an effect by cyclic AMP. Imunopharmacol 39 (1998) 181-191
41. Shin H.S., and Slattery J.T. CYP3A4-mediated oxidation of lisofylline to lisofylline 4,5-diol in human liver microsomes. J Pharm Sci 87 3 (1998) 390-393
42. McLellan R.A., Drobitch R.K., Manshouwer M., and Renton K.W. Fluoroquinolone antibiotics inhibit cytochrome P450-mediated microsomal drug metabolism in rat and human. Drug Metab Dispos 24 10 (1996) 1134-1138
43. Sartor R.B. Therapeutic manipulation of the enteric microflora in inflammatory bowel disease: antibiotics, probiotics and prebiotics. Gastroenterology 126 6 (2004) 1620-1633
44. Castiglione F., Rispo A., Di Gorolamo E., Cozzolino A., Manguso F., Gassia R., et al. Antibiotic treatment of small bowel bacterial overgrowth in patients with Crohn's disease. Aliment Pharmacol Ther 18 11-12 (2003) 1107-1112